Article Type
Changed
Mon, 01/14/2019 - 14:54
Display Headline
Dual bronchodilator combination shines in patients with high-risk COPD

It may be time to revise guidelines when it comes to initial treatment of chronic obstructive pulmonary disease (COPD) complicated by exacerbations, based on data from a phase III trial reported at an international conference of the American Thoracic Society. The trial, known as FLAME, undertook a head-to-head comparison of 2 inhaled drug combinations (indacaterol and glycopyrronium vs salmeterol and fluticasone) among more than 3300 patients from 43 countries. After a year, the annual rate of exacerbations was 11% lower with indacaterol-glycopyrronium than with salmeterol-fluticasone. More on the results of the trial is available at Family Practice News: http://www.familypracticenews.com/specialty-focus/pulmonary-sleep-medicine/single-article-page/dual-bronchodilator-combination-shines-in-patients-with-high-risk-copd/60032e8e9b0393af639f41566f165d80.html.

References

Author and Disclosure Information

Publications
Legacy Keywords
COPD, chronic obstructive pulmonary disease
Sections
Author and Disclosure Information

Author and Disclosure Information

It may be time to revise guidelines when it comes to initial treatment of chronic obstructive pulmonary disease (COPD) complicated by exacerbations, based on data from a phase III trial reported at an international conference of the American Thoracic Society. The trial, known as FLAME, undertook a head-to-head comparison of 2 inhaled drug combinations (indacaterol and glycopyrronium vs salmeterol and fluticasone) among more than 3300 patients from 43 countries. After a year, the annual rate of exacerbations was 11% lower with indacaterol-glycopyrronium than with salmeterol-fluticasone. More on the results of the trial is available at Family Practice News: http://www.familypracticenews.com/specialty-focus/pulmonary-sleep-medicine/single-article-page/dual-bronchodilator-combination-shines-in-patients-with-high-risk-copd/60032e8e9b0393af639f41566f165d80.html.

It may be time to revise guidelines when it comes to initial treatment of chronic obstructive pulmonary disease (COPD) complicated by exacerbations, based on data from a phase III trial reported at an international conference of the American Thoracic Society. The trial, known as FLAME, undertook a head-to-head comparison of 2 inhaled drug combinations (indacaterol and glycopyrronium vs salmeterol and fluticasone) among more than 3300 patients from 43 countries. After a year, the annual rate of exacerbations was 11% lower with indacaterol-glycopyrronium than with salmeterol-fluticasone. More on the results of the trial is available at Family Practice News: http://www.familypracticenews.com/specialty-focus/pulmonary-sleep-medicine/single-article-page/dual-bronchodilator-combination-shines-in-patients-with-high-risk-copd/60032e8e9b0393af639f41566f165d80.html.

References

References

Publications
Publications
Article Type
Display Headline
Dual bronchodilator combination shines in patients with high-risk COPD
Display Headline
Dual bronchodilator combination shines in patients with high-risk COPD
Legacy Keywords
COPD, chronic obstructive pulmonary disease
Legacy Keywords
COPD, chronic obstructive pulmonary disease
Sections
Article Source

PURLs Copyright

Inside the Article